Oncocyte (NASDAQ:IMDX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Oncocyte (NASDAQ:IMDX) from a sell rating to a hold rating in a research report report published on Saturday morning,Wall Street Zen reports.

A number of other analysts have also commented on IMDX. Needham & Company LLC reissued a “buy” rating and set a $9.00 price target on shares of Oncocyte in a research note on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a research report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Oncocyte has a consensus rating of “Hold” and an average price target of $10.50.

Oncocyte Stock Performance

Shares of NASDAQ:IMDX opened at $4.00 on Friday. Oncocyte has a 52-week low of $2.42 and a 52-week high of $8.51. The company has a market capitalization of $130.88 million, a PE ratio of -2.68 and a beta of 1.80. The company has a fifty day moving average of $4.41 and a 200-day moving average of $4.72.

Oncocyte (NASDAQ:IMDX) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.24 million during the quarter.

About Oncocyte

Oncocyte Corporation is a molecular diagnostics company focused on developing and commercializing tests intended to support cancer treatment decisions. Its technologies use genomic and other molecular information to help physicians assess disease characteristics, recurrence risk, and potential response to therapy.

The company’s historical product portfolio has included DetermaRx, a genomic test designed to identify patients with early-stage lung cancer who may face a higher risk of recurrence after surgery, and DetermaIO, which was developed to help evaluate the tumor immune environment and potential response to immunotherapy.